Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers broke down the various strategies that the gay men in the Opposites Attract study used to prevent HIV transmission.
Women in a global study began an HIV treatment regimen based on one of the two drugs after 20 weeks of gestation.
But gay men living with untreated HIV did see higher viral loads if they also had a sexually transmitted infection, says a new study.
The Campbell Foundation’s latest grant funds research into the RV144 trial in Thailand, which showed 31 percent protection against HIV.
Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.
The study of mixed-HIV-status gay couples prompted the CDC to conclude that undetectable people have effectively no risk of passing on HIV.
Continuously providing such infants with antiretrovirals as early as possible limits the size of the reservoir.
A new HIV vaccine regimen was well tolerated and elicited a good immune response among participants of a study who did not have the virus.
The vaccine prompted a robust immune response against HIV in those without the virus; now researchers hope to move it into advanced trials.
Between this study of mixed-HIV-status gay couples and a similar previous study, partners have engaged in about 35,000 condomless sex acts.
Researchers added more power to the vaccine that showed modest protection against humans in Thailand in 2009.
With a major new HIV vaccine trial under way, cautious optimism is stirring that the vaccine will prove effective enough for a rollout.
Thailand is the first Asian country to reach the goal.
A new analysis of the global iPrEx trial has found that American participants adhered relatively well to Truvada as pre-exposure...
Most foreign volunteers who participated in the clinical trial that first proved Truvada prevents HIV no longer have access to the drug.
Key issues addressed included intellectual property, patent updates, pharmaceutical negotiations and outreach to at-risk populations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.